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Abstract The present study describes the production of
hyaluronan based porous microparticles by a semi-contin-
uous gas anti-solvent (GAS) precipitation process to be
used as a growth factor delivery system for in vivo treat-
ment of ulcers. Operative process conditions, such as
pressure, nozzle diameter and HYAFF11 solution con-
centrations, were adjusted to optimize particle production
in terms of morphology and size. Scanning electron
microscopy (SEM) and light scattering demonstrated that
porous nano-structured particles with a size of 300 and
900 nm had a high specific surface suitable for absorption
of growth factors from the aqueous environment within the
polymeric matrix. Water acted as a plasticizer, enhancing
growth factor absorption. Water contents within the HY-
AFF11 matrix were analyzed by differential scanning
calorimetry (DSC). The absorption process was developed
using fluorescence dyes and growth factors. Immunohis-
tochemical analysis confirmed the high efficiency of
absorption of growth factor and a mathematical model was
generated to quantify and qualify the in vitro kinetics of
growth factor release within the polymeric matrix. In vivo
experiments were performed with the aim to optimize
timed and focal release of PDGF to promote optimal tissue
repair and regeneration of full-thickness wounds.
1 Introduction
Growth factors are polypeptides that transmit signals to
modulate cellular activities. Growth factors can either
stimulate or inhibit cellular proliferation, differentiation,
migration, adhesion and gene expression [1]. One way of
enhancing the in vivo efficacy of growth factors is to
facilitate the sustained release of bioactive molecules over
an extended time period by their incorporation into poly-
mer carriers. Implantation of a drug delivery device
directly into the tissue in need of treatment facilitates
localized drug delivery. Delivery systems have been
designed in a variety of configurations and have been
fabricated from different types of natural and synthetic
polymers (degradable, non-degradable) [2–4]. These devi-
ces have a common ability to control the release of
bioactive proteins for extended periods of time by different
mechanisms [5]. Through incorporation into polymeric
devices, protein structure and thus biological activity can
be stabilized, prolonging the length of time over which
growth factors are released at the delivery site. The period
of drug release from a polymer matrix can be regulated by
the drug loading, type of polymer used and the processing
conditions. Adverse processing conditions that cause pro-
tein aggregation or denaturation have to be avoided.
In biodegradable carriers, growth factor release is con-
trolled by the polymer matrix’s rate of degradation, which
causes changes in the morphological characteristics of the
materials, such as porosity or permeability [6, 7]. The use
of porous materials offers advantages that are particularly
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important for drug release systems: (i) higher specific
surface for the adsorption/release of active components and
(ii) enhancement of the drug release rate for erodible par-
ticulate systems. These two aspects are particularly
relevant for particles that have nano-structured porosity
[8, 9].
These particles are usually produced by double emul-
sion-solvent evaporation or spray drying techniques. The
limits associated with these processes are excessive use of
organic solvent, which leads to pollution of the product and
waste disposal problems, toxicity for incomplete solvent
removal and thermal and chemical degradation of sub-
stances [10]. Other techniques, such as spray drying,
operate at temperatures that can thermally denature ther-
mosensible compounds, such as proteins. New techniques
based on high-pressure gas anti-solvent (GAS) have shown
great potential [11], with the advantages of being envi-
ronmentally safe and preserving the properties of thermally
labile compounds. The GAS processes have been shown to
produce different types of biopolymeric morphologies at
mild temperatures (293–313 K) with an amount of residual
organic solvent lower than that recommended by FDA.
In the present report, hyaluronan-based porous nano-
particles, obtained with a high-pressure CO2 anti-solvent
technique, were produced and used as growth factors
delivery systems for in vivo treatment of skin ulcers. The
particles had a nano-structured porosity that was particu-
larly suitable for absorbing bioactive molecules.
HYAFF11, the benzyl ester of hyaluronic acid (Fidia
advanced Biopolymer, Italy), is a biopolymer well known
in tissue engineering applications such as in vitro recon-
struction of skin, cartilage, and bone, and has been recently
used for the in vivo regeneration of small arteries [12–16].
Microparticles, films or plugs prepared from hyaluronan
esters have also been evaluated as a novel drug delivery
system [17, 18]. In this study, PDGF was embedded in
HYAFF microparticles as a delivery system designed to
improve full-thickness wound repair. HYAFF microparti-
cles have the ability to absorb different growth factors,
cytokines and bioactive peptide fragments and to release
them in a temporally and spatially specific event-driven
manner. This timed and focal release of cytokines,
enzymes and pharmacological agents should promote
optimal tissue repair and regeneration of full-thickness
wounds. We tested PDGF because it is a potent activator
for cells of mesenchymal origin, and a stimulator of che-
motaxis, proliferation and new gene expression in
monocytes, macrophages and fibroblasts, accelerating
ECM deposition [19, 20]. This family of growth factors
exists in both homo- and heterodimeric forms and several
authors reported that a single application of PDGF-BB to
an incisional wound increased the neoangiogenesis through
enhancement of endogenous PDGF-BB signalling [21].
Moreover, PDGF and its relative proteins were the first
approved proteins for promoting diabetic foot healing and
other chronic nonhealing ulcers. Since 1986, Knighton
et al. reported their successful treatment of chronic ulcers
with autologous platelet-derived wound healing formula
(PDWHF) [22]. In the present study, our aim was to opti-
mize timed and focal release of PDGF to promote optimal
tissue repair and regeneration of full-thickness wounds.
2 Materials and methods
2.1 Materials
The biomaterial used in the present study was derived from
the total esterification of hyaluronan (synthesized from
80 kDa to 200 kDa sodium hyaluronate) with benzyl alco-
hol, and is referred to as HYAFF11. The final product is an
uncrosslinked linear polymer with an undetermined
molecular weight; it is insoluble in aqueous solution yet
spontaneously hydrolyzes over time, releasing benzyl
alcohol and hyaluronan. HYAFF11was used to create non-
woven meshes of 50 lm-thick fibers, with a specific weight
of 100 g/m2. These devices were obtained from Fidia
Advanced Biopolymers (FAB, Abano Terme, Italy) [23].
2.2 Film production
Films were developed by solvent casting of 10% (w/w)
HYAFF11/DMSO solution: 0.5 ml were placed on a glass
support and spread with a spatula; solvent was evaporated
in an oven at 338 K for 30 min. The film was then peeled
from the glass support.
2.3 Polymer particle production: process description
Production of microparticles was performed using a semi-
continuous GAS process and the apparatus shown in Fig. 1.
An exhaustive description of the process has been reported
by Elvassore et al. [24]. Briefly, in the GAS precipitation
process, a polymeric organic solution and the supercritical
antisolvent were continuously added to the precipitation
unit in co-current mode. The organic solution was atomized
into small droplets within the high-pressure precipitation
unit. The high-pressure GAS induced polymer precipitation
from the organic solution, yielding nano- and microparti-
cles that were collected at the bottom of the vessel. A
washing step was carried out to extract the residual organic
solvents to the desired amount.
A schematic description of the operative procedure
follows: after steady conditions of pressure, temperature
and CO2 flow rate were reached, the organic solution was
atomized through a fused silica capillary nozzle into a
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200 cm3 high pressure vessel by a high-pressure liquid
chromatography (P1) pump. Temperature control was
achieved by a heat exchanger (TB2) connected to an aux-
iliary bath (RF). Cell temperature was measured by two Pt
100X resistances placed at the top and the bottom of the
vessel and CO2 flow rate was controlled by two fine
metering valves (V5, V6) and measured with a dry flow-
meter (FM).
The antisolvent (CO2) was fed by a reciprocating pump
(P2) from the top of the cell. It was then vented through
expansion valves (V5, V6) and expansion units (EU, ST).
The valves and the outline of CO2 were heated by a ther-
mostatic bath (TB1) to prevent freezing due to CO2
depressurization.
At the end of the experiment, the polymer microparticles
were recovered at the bottom of the vessel on 0.22 lm-
filters (Millipore, type GS).
2.4 Particle morphology analysis
Particle morphology was investigated by scanning elec-
tron microscopy (SEM) (Stereoscan 440, Leica
Cambridge). The sample was dispersed in milli-Q water
and sonicated for 45 min through an Ultrasonic cleaner
(CP104, Vetrotecnica, Italy) in order to break particle
aggregates. Samples were then centrifuged for 5 min at
2,000 rcf (Megafuge 1.0, Heraeus) and the supernatant
was removed. This operation was repeated for 4 or
5 times in order to remove smaller fragments. 0.1 ml of
water containing polymer particles was placed on a glass
support and after natural evaporation of liquid, particles
were gilded (Polaron, SEM coating system) and observed
by SEM.
Particle size was evaluated by light scattering. 0.5 mg of
microparticles was dispersed in milli-Q water and soni-
cated for 30 min (Ultrasonic cleaner, 65% power). The
undivided material was discarded. The two phases were
then separated by centrifuge at 2,000 rpm for 30 s. After-
wards, the diameter range in each phase was determined by
light scattering (DLS Nicomp 380, Particle Sizing Systems,
Inc. Santa Barbara, USA). Finally, water was evaporated
under a vacuum and particles were weighed in order to
determine the percentage of each phase.
2.5 Water content
Differential scanning calorimetric (DSC) spectra was per-
formed in order to determine water content in HYAFF11
50 lm-thick films. A total of 1 mg of polymer sample,
previously immersed in pure water for 1 h and dried at
room temperature for 3 h, was analysed by DSC (Q10, TA
Instruments) with a ramp heating process from 303 K to
423 K at a rate of 10 K/min. The same analyses were
performed on wetted samples dried in a vacuum at room
temperature for 15 h, and on samples further dried in an
oven at 378 K for 15 h. The quantity of evaporated water
could be determined by analyzing the absorbed heat
spectra.
2.6 Polymer impregnation
Impregnations were performed both in particles and in
films with water soluble dyes (fluorescein [10 lg/ml]) and
growth factors (PDGF [0.5 lg/ml]) by means of solution
deposition on samples for different contact times (1 min,
5 min, 60 min, 24 h and 72 h).
Fig. 1 Schematic view of
experimental apparatus.
P: precipitation vessel; P1: high-
pressure liquid chromatographic
pump; P2: CO2 pump; S:
solution vessel; FT: filter; V1,
V2: fine metering valves; V3,
V4: on-off valves; V5, V6:
expansion valves; V7: discharge
valve; HE: heat exchangers;
GC: CO2 cylinder; RF:
refrigerating device; TB1,
TB2: thermostatic baths;
EU: expansion unit; ST: solvent
recovering unit; FM: flow
meters; R: rotator; F: aspiration
system. (—) high pressure
tubing; (—) water line for
temperature control
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2.7 Analysis of impregnation
2.7.1 Qualitative analysis
The depth of dye absorption was investigated by analyses
of serial 7-lm-thick cryosections of the film. Briefly, films
were embedded in medium for frozen tissue specimens
(Tissue-Tek OCT, Sakura Finetek, USA) and frozen. Serial
7-lm-thick cryosections were cut by ultramicrotome,
mounted on gelatin-covered slides and observed with
microscopy.
Growth factor superficial impregnation on particles was
qualitatively evaluated by immunohistochemical analysis.
Rabbit PDGF anti-human monoclonal antibodies
(1/100) were used. The avidin-biotin complex technique
(Vectastain-ABC kit; Vector, Burlingame, CA) was used to
reveal the immunoreaction. Microparticles were developed
for 20 min in peroxide substrate solution containing 3,30-
diaminobenzidine and hydrogen peroxide and at the end
were counterstained with Mayer’s hematoxylin. Negative
control specimens were prepared using sections incubated
without the primary antibody. A brown coloration appeared
if the growth factor had been absorbed.
2.7.2 Quantitative analysis
Quantification of impregnated growth factor were tested by
ELISA (SIGMA) analysis.
Growth factor release from HYAFF particles were
detected in presence of Hyaluronidase (Sigma) [0.5% and
5%] or Na2CO3 [1, 5, 10 50 lg/ml] added to the medium.
2.8 Wounding and preparation of wound tissue
The protocol was approved by the Institutional Animal
Care Committee of Padova University. A total of 18 male
Wistar rats weighing 250–350 g were subjected to the
surgical procedures under halothane anesthesia. The back
was shaved and three circular excisional wounds of 1.0 cm
diameter were generated that extended beyond the pan-
niculus carnosus (full thickness wounds) using a surgical
scalpel. The three wounds on the back of one animal were
at least 1.5 cm apart from each other. All wounds were
covered with a semi-occlusive polyurethane dressing
(Tegadermd, 3 M, St. Paul, MN). Wounds were divided
into three groups. One group was treated with PDGF
Embedded Microparticles (PEMs) [2 mg microparticles
embedded with PDGF 0.01%/ml of inert gel], the other two
were treated with vehicle gel only (Inert gel: I) and inert
gel plus untreated microparticles (M) [2 mg microparticles/
ml of inert gel], respectively. All wounds received twice
weekly a dose of 7.0 mg/cm2 of proper gel. At time
intervals ranging from 3 days through 21 days after
wounding, the rats were killed with an overdose of barbi-
turates (Nembutal sodium solution; Abbott Laboratories),
and wounds were excised with a 2 mm rim of surrounding
tissue. Samples were fixed in 10% buffered formalin or
immediately frozen in liquid nitrogen for the following
analysis. All surgical procedures were performed in an
identical fashion by a single surgeon. No prophylactic
antibiotic was administered and the animals were fed an
unrestricted standard diet.
2.9 Wound photography and analysis
Standardized photography of the wound was performed
prior to the initial dressing, following grafting, and daily
thereafter. The entire bolster was changed at the time of
daily photography. A single lens reflex camera with a
macro lens was mounted on a camera stand. The macro
lens setting was fixed at a 2:1 reproduction setting, and ISO
100 slide film used. A centimeter ruler was included in
each photograph. The photographs were analyzed and an
arbitrarily sized designated analysis area (DAA) was
selected from a central area of each wound [25]. Using
photographic slide scanning and digital planimetric soft-
ware, the wounds were analyzed as reported by Harries
et al. [25]. The areas remaining open within the DAA of
each wound were measured. Neoepithelial areas (NEA)
were calculated by subtracting daily wound areas from
original wound areas. The percentage of neoepithelializa-
tion (%NE) was then determined for the DAA by the
equation percentage NE = (NEA/DAA) 9 100 [25]. This
percentage NE was used as the percentage of healed
wounds for determining treatment effect. Data from each
day were compared among the four groups by one-way
analysis of variance and between pairs of groups by Fish-
er’s least significance difference test with an alpha value of
0.05.
2.10 Histological and morphological analyses
For histological analyses, specimens were fixed in forma-
lin, paraffin-embedded, and stained with haematoxylin and
eosin. For immunohistochemical analyses, cryostatic sec-
tions (7 lm) were used. These were layered over gelatin-
coated glass slides, fixed with absolute acetone for 10 min
at room temperature, and cryopreserved at -20C until
use.
Collagen type I (Coll-1), fibroblasts (FU) and endothe-
lial cells (CD 31) were visualized with the acid
phosphatase anti-acid phosphatase (APAAP) procedure.
Reactions were conducted in humidified chambers at room
temperature. Briefly, after saturating non-specific antigen
sites with 1:20 rabbit serum in 0.05 m maleate TRIZMA
(Sigma) pH 7,6 for 20 min, the first antibody was added to
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samples (1:800 collagen type I-DAKO). After an incuba-
tion of 2 h, samples were rinsed with buffer solution, and
the second antibody was added for 30 min (Link Ab-
DAKO-, rabbit anti-mouse). After rinsing, the cryostatic
sections were incubated for 30 min with 1:50 mouse AP-
AAP Ab-DAKO, rinsed again, and lastly, reacted for
20 min with the Fast Red Substrate (Sigma). Counter
staining was performed with haematoxylin (Sigma).
2.11 Semi-quantitative analysis of cells
In order to analyze the cellular response to treatments,
masked microscopic examinations were performed on
immunostained sections. Cells were identified by: haema-
toxylin and eosin staining for inflammatory cells;
immunohistochemical staining for endothelial cells (posi-
tive for CD 31); fibroblasts and type I collagen. Briefly, two
investigators analyzed in a masked fashion at least 3 slides
for each experiment by light microscopy using 209 as the
initial magnification. Each slide contained 3 sections of
specimen and 5 fields of 322 lm2 each were analyzed for
each tissue section. Experiments were performed at least
three times and values were expressed as the mean ± SD.
3 Results
3.1 Particle characterization
In order to obtain micro- and nano-particles with a high
specific surface, we performed different experiments
investigating the influence of process variables, such as
polymer-solvent mixture concentrations and injection flow
rates, nozzle diameters and pressures. Table 1 summarizes
the operative process conditions used in different experi-
ments; the temperature at which the experiment was
performed is reported for completeness.
We initially observed that the 250 lm nozzle diameter
(tests n. 1 and 2) produced large particles with a size
around 100 lm (data not showed). These particles were
compact and had a microporosity as reported in the scan-
ning electron micrographs (Fig. 2).
Experiments performed with the 100 lm diameter
nozzle (experiment 3) and 0.7% (w/w) HYAFF11/DMSO
resulted in a large amount of stable micro-particle aggre-
gates (data not shown). Experiments 4 and 5, performed
with the same nozzle of experiment 3 (100 lm) but with a
lower concentration of polymer solution (0.3% and 0.5%
instead of 0.7% w/w), produced a fine, dry particulate
matter. This powder was collected in large agglomerates
that were easily dispersed in water by a sonication treat-
ment of 20 min and observed by SEM. Figure 3 shows a
fraction of large particles or stable particle agglomerates
with dimensions ranging between 1 lm and 5 lm and a
fraction of sub-micrometric particles. Figure 3 also shows
that the particulate product obtained under the conditions
of experiment 4 was formed by stable agglomeration of
nano-particles. This finding was particularly important
since micrometric or sub-micrometric particles have a
nano-structured porosity and, consequentially, a very high
specific surface.
In order to further reduce particle dimension, we inves-
tigated the effect of decreasing the nozzle diameter to 50 lm
and increasing the pressure of the process (experiments 6
and 7 in Table 1). With this small diameter (50 lm), nozzle
occlusion problems during solution injection led to poor
productivity and reproducibility. Conversely, higher pres-
sure (200 bar; experiment 7) resulted in micro-particles with
the same morphological structure as those produced in
experiments 4 and 5 (data not shown).
Particle size distribution was studied by light scattering,
and the results are summarized in Table 2. The operative
conditions of experiments 1, 2 and 6 were not considered
suitable for particle production.
An example of typical particle size distribution analyzed
by light scattering is reported in Fig. 4. A typical bimodal
distribution around 300–400 and 900 nm was obtained for all
experiments reported in Table 2, which also reports the
weight-based fraction of nano-particles belonging to the
large (900 nm) and small (300–400 nm) size range.
Table 1 Summary of operative


















1 0.3 6.0 250 15 25
2 1.0 6.0 250 15 21
3 0.7 5.0 100 15 24
4 0.5 6.0 100 15 28
5 0.3 6.0 100 15 30
6 0.3 1.5 50 15 23
7 0.3 5.6 100 20 21
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As reported in Table 2, the particles obtained with the
100 lm nozzle and with various polymer concentrations
(experiments 3, 4 and 5) resulted in no change in particle
size. However, under these operative conditions, a small
Fig. 2 Scanning electron
micrographs of experiment 1
(Process conditions: 15 MPa,
0.3% (w/w) HYAFF11/DMSO
solution, 250 lm nozzle
diameter): (a) 1,0009, (b)
3,0009
Fig. 3 Scanning electron
micrographs of experiment 4
(Process conditions: 15 MPa,
0.5% w/w HYAFF11/DMSO
solution, 100 lm nozzle
diameter): (a) 12,0009; (b)
21,0209
Table 2 Summary of light scattering analysis of volume weighted
sizes and weight based fraction of nano-particles fabricated by gas
anti-solvent precipitation process. The operative condition used for
experiments 1, 2 and 6 did not yield particulate products. The bimodal
particle size distribution was observed for experiments 4 and 7
Experiment
no.











3 400 ± 100 – 1,000 ± 120 *100
4 400 ± 112 83 900 ± 135 17
5 380 ± 61 – 900 ± 81 *100



















Fig. 4 Size distribution of nanoparticles of HYAFF11 obtained by
GAS process (experiment 7, Process conditions: 20 MPa, 0.3% (w/w)
HYAFF11/DMSO solution, 100 lm nozzle diameter). The insert
shows a canning electron micrograph of small size particles produced
in experiment 7 (51,2009)
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change in HYAFF11/DMSO concentration resulted in a
dramatic change in the percentage of small and large par-
ticle fractions. For instance, experiment 4 (0.5% instead
0.7% or 0.3% w/w HYAFF11/DMSO concentration)
yielded only 17% particles of 900 nm size, whereas
experiments 3 and 5 yielded approximately 100% large
size particles.
The optimal experimental conditions in terms of mor-
phology, particle dimension and fraction of small particles
were those used in experiment 7. A higher operative
pressure (200 bar) led to reproducible production of small
particles with a typical size of 270 ± 78 nm. The weight-
based fraction of large particles with a size of
900 ± 135 nm was only 25%. The light scattering analysis
recorded for experiment 7 showed that 90–98% of particles
had a diameter smaller than 1,000 nm. The nano-particles
produced under the operative conditions of experiment 7
had a nano-structured porosity and high specific surface.
3.2 Absorption process
Because water can act as a plasticizing agent on the
polymeric matrix, thereby enhancing the solute absorption
from aqueous solution, the water content within the 50 lm
thick polymeric film was evaluated by DSC analysis and
found to be 8.5% (w/w). Samples dried in a vacuum at
room temperature for 15 h had a 5.5% (w/w) water content.
This amount was reduced to 3.7% (w/w) with further
sample treatment in an oven at 378 K for 15 h. These
results demonstrated the ability of the polymeric matrix to
permanently absorb high amounts of water, which acted as
a plasticizing agent that enhanced absorption of bioactive
molecules.
In order to evaluate the time-scale of the absorption
phenomena, dye diffusion within 50 lm thick polymeric
films was studied. Figure 5 shows the images of a cross
section of the HYAFF11 films impregnated with 10 lg/
ml of sodium fluorescein for different incubation times:
5 min, 60 min, 24 h and 72 h. After 1 and 5 min, the
surface was impregnated up to 25.4 ± 0.9 lm; after 10 to
30 min the coloured layer became thicker and after 60 min
the dye started to be visible in the centre of the polymeric
film. After 24 h, the color distribution was almost homo-
geneous (less signal was observed in the centre of films),
whereas a uniform dye concentration was observed after
72 h.
An estimation of the diffusion coefficient (Ddye) was
obtained by fitting the penetration depth (z) of the dye
estimated from the fluorescence images of the polymeric
film cross section reported in Fig. 6. These experimental
data were correlated using the following equation [26],
which describes the time evolution of diffusing molecules










where cdye is the molar dye concentration, cdye;0 at baseline
and z = 0, the depth (z) corresponds to the penetration
Fig. 5 Microphotographs (109
magnification) of 100 lm thick
HYAFF11 films impregnated
with 10 mg/l sodium fluorescein
by an aqueous-solution contact
method: (a) after 5 min, (b)
after 60 min, (c) after 24 h and















Fig. 6 Depth of sodium fluorescein penetration into HYAFF11
films as a function of contact time. The concentration of sodium
fluorescein solution used was 10 lg/ml. The line was obtained by the
fitting of data using Eq. 1
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length (distance from film surface to the depth where the
sodium fluorescein started to be detected). This dye dif-
fusion coefficient, Ddye, was calculated to be
1.2 9 10-9 ± 0.2 9 10-9 cm2/s.
3.3 Growth factor release
In vitro release profiles give important information on the
efficiency of the delivery system for the controlled release
of drugs. An ‘‘in vitro’’ drug release study is indeed a
prerequisite to obtaining correct predictions in order to
design and test the ‘‘in vivo’’ activity of controlled drug
delivery forms.
In the present study, particles are suspended in a small
volume of receiving medium (2 ml) in order to reproduce
topical administration of HYAFF11 microspheres
(Fig. 7). The amount of drug released (expressed as ng
of growth factors/mg microspheres) is plotted versus
time. Data represent the mean of six independent
experiments. Although native HA is able to dissolve
rapidly in water, benzyl esters of hyaluronan show dif-
ferent behaviour possibly because of the different nature
of the polymer. As reported in literature [27, 28] it is
well known that in vitro growth factor release from
HYAFF11 is not observable at early (namely within
15 days) stages in physiological (pH 7) conditions. Since
they are composed of hyaluronan benzyl esters, HYA-
FF11 scaffolds,form a gellified network from which drug
release can be controlled for long periods of time in
culture medium [29].
As reported in Fig. 8, the presence of hyaluronidase in
the medium did not induce polymer degradation. These
observations confirm that the carboxylic groups in the beta-
glucoronic acid unit are the activation centre of this
enzyme and that total blockage of these groups can restrict
the cleavage of beta (1–[4) glycoside bonds by this
enzyme [30–32]. Only in the presence of an alkaline
environment (obtained by the addition of 5% Na2CO3) is a
rapid degradation of HYAFF11 microspheres observable.
Analyzing the release profiles, one can observe that the
progressive increase of Na2CO3 increased the release rate
of the PDGF and TGF b (Fig. 9). In vitro PDGF and TGF
b release profiles from impregnated micro and nano-par-
ticles are reported in Fig. 9 for different sodium carbonate
concentrations. The maximum value of PDGF and TGF b
released corresponded to the amount of growth factor
absorbed in the micro-particles and was estimated to be
0.9 ng/mg.
In order to analyze the release mechanisms and their
dependence on Na2CO3, the experimental release profiles
were fitted with the following equation developed for drug
release from erodable polymeric particles with spherical
shapes [33]:
Fig. 7 Microphotographs (a) 59, (b) 209 magnification) demon-
































Fig. 8 In vitro release of TGF-b (a) and PDGF (b) from impregnated
microparticles as a function of time for different Hyaluronase
concentrations
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Mt=M1 ¼ 1  1  K  tð Þ3 ð2Þ
where Mt/M? represents the drug fraction released at the
time t; Mt and M? represent the cumulative absolute
amount of drug released at time t (min) after the addition of
Na2CO3 and at infinite time, respectively. K is a constant
that depends on the surface erosion rate constant (keros), the
initial concentration of growth factor in the matrix (C0) and
the radius of the microspheres (R) at t = 0 as follows [31]:
K ¼ keros=C0R ð3Þ
In Fig. 10a, fair model correlations of experimental release
data for PDGF/TGF b are reported; the same correlations
were obtained for (data not shown). Polymer erosion was
due to the action of Na2CO3. For this reason, the K values
were plotted against the concentration of Na2CO3 and a
linear correlation was observed (Fig. 10b). The values
obtained for a Na2CO3 concentration of 50 lg/l were not
considered because in this case a fast dissolution (less than
7 h) of growth factors was obtained and no experimental
data were collected during this time period.
These results indicated that the growth factor release
was mainly driven by the polymeric matrix erosion pro-
cess. This is of fundamental importance in designing a
proper release rate in vivo. In conclusion, the rate of
polymer erosion and thus the growth factor release
increased linearly with increasing Na2CO3 concentrations,
thus it was possible to control the rate of release by
changing the Na2CO3 concentration or the pH of the
solution.
3.4 In vivo treatment
PDGF embedded microparticle treatment shows a trend in
wound healing stronger than the vehicle control (inert gel:
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Fig. 9 In vitro release of TGF-b (a) and PDGF (b) from impregnated
microparticles as a function of time for different Na2CO3 concentra-
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Fig. 10 Experimental and mathematical comparisons: (a) experi-
mental and mathematical modelling of in vitro cumulative TGF-b
fractions released as a function of time for different Na2CO3
concentrations. The lines corresponded to data fitting by Eq. 2. (b)
Linear correlation of K as a function of Na2CO3 concentration for
both TGF-b and PDGF release
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(Fig. 11). Epithelialization kinetics showing superiority of
PDGF embedded microparticle at closing circular wounds.
Percent healed wounds directly reflected the percentage of
neoepithelialization of the wounds. Although breaking
strength in all wounds increased over the entire 12-day
period, PDGF embedded microparticle treatment still
resulted in significantly stronger wounds on day 5 com-
pared to the vehicle.
3.5 Cellular response to scaffolds
Cellular events involved in wound healing are summarised
in Table 3.
At day 3, ‘‘I’’ treatment showed slow infiltration of
granulocytes and macrophages whereas M and PEM
showed a moderate amount of macrophages, fibroblasts
and some granulocytes. No collagen fibers were observable
in any wounds; scarce endothelial cells were present only
in PEM-treated tissue.
At day 5 and 7, ‘‘I’’ treatment showed a moderate
infiltration of granulocytes and macrophages whereas M
and PEM showed larger amounts of macrophages, some
granulocytes and few giant cells recruited to digest the
microparticle polymer. The cellular response to M and
PEM treatment at these time points, included a significative
amount of endothelial cells and some fibroblasts. Collagen
fibers were present overall in PDGF-treated tissue.
At day 14, M and PEM treated tissues showed a mod-
erate amount of macrophages and fibroblasts throughout
the scaffold and some non-phagocytic cells were present. A
larger amount of macrophages and fibroblasts accompanied
by some non-phagocytic cells were found throughout the
wounds treated with M and PEM. At day 21, all the
wounds were closed.
4 Discussion
This study aimed to produce HYAFF11 micro and nano-
particles by a GAS technique. Appropriate experimental
conditions resulted in the production of HYAFF11 based
microspheres characterized by spherical shape, absence of
aggregates and an almost perfect quantitative recovery.
Several authors obtained HYAFF11 microparticles for






















Fig. 11 Epithelialization kinetics of vehicle control (inert gel: I) or
Microparticles (M) with out growth factors treated wounds PEM
(PDGF Embedded Microparticles) at closing interstices of rat split-
thickness skin grafts. The percentage healed reflects the percentage
neoepithelialization of the interstitial spaces. Bars represent
mean ± SD
Table 3 Cellular response to scaffolds. Cells were scored from not present (-) to abundantly present (???)






3 I ? - ? ? - -
M ? ? ? ?? - -
PEM ? ? ? ?? ? -
5 I ?? ? ? ? ? ?
M ?? ?? ? ?? ?? ?
PEM ?? ?? ?? ??? ?? ??
7 I ?? ?? ? ?? ? ?
M ?? ?? ?? ?? ?? ??
PEM ?? ?? ?? ??? ??? ???
14 I ?? ?? ?? ?? ?? ??
M ?? ?? ? ??? ??? ???
PEM ?? ?? ? ??? ??? ???
The absolute numbers of PMNs and non-phagocytic cells are lower than for phagocytic cells
a PMNs = polymorphic nuclear cells, i.e. granulocytes
b Phagocytic cells include macrophages and monocyte-derived giant cells
c Non-phagocytic cells include lymphocytes, plasma cells and mast cells
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and organic solvents [17]. These techniques are not flexible
and the final products are often characterised by a high
residual solvent content, low drug loading, drug degrada-
tion or denaturation, ineffective drug release and unsuitable
physical and morphological properties. Supercritical or
compressed fluid based techniques were used for the
preparation of micro- and nanoparticulate products with
pharmaceutical requisites (solvent free, suitable techno-
logical and biopharmaceutical properties, high quality). In
the GAS precipitation process, the organic solution of the
substances, which must be micronized, was sprayed into a
vessel filled with dense CO2 at a suitable temperature. The
use of CO2 diffusion within the small droplets of polymeric
organic solution led to a reduction of solvent concentration.
The CO2 acts as antisolvent, and its efficiency depends on
the pressure inside the precipitation chamber. The mini-
mum value of CO2 pressure at which there was
precipitation of HYAFF11 was 100 bar at 313 K [11].
For this reason, all the experiments were carried out at a
pressure equal to or higher than 160 bar.
When using high polymer concentrations (1% w/w), a
large nozzle diameter (250 lm) and/or a low flow rate, the
solution jet did not break into small droplets and sponges or
other products with a smooth surface were obtained. The
spray regime and jet break-up was favoured by a low
solution viscosity, small nozzle diameter, high injection
flow rate, and high density of the environment in which the
solution was atomized [19]. This latter aspect was partic-
ularly relevant and was related to the CO2 density within
the precipitation chamber.
Very small particles were obtained when a polymeric
solution of 0.3% (w/w), a nozzle of 100 lm, a pressure of
200 bar and a flow rate of 5.6 ml/min were used. The
distribution of the particle size was bimodal.
One experimental strategy used to obtain growth factor
loaded micro-particles was the co-precipitation of growth
factor and HYAFF11 by the semi-continuous GAS tech-
nique starting from a homogenous solution of protein and
polymer. This technique has been previously used for
insulin loading [19]. We found that the particles produced
using this strategy possessed the correct morphology but
the growth factor was poorly loaded and was not active
(data not shown). This inactivation was probably due to
growth factor denaturation resulting from high shear stress
during the atomization process and/or the effect of the
solvent: DMSO is able to denature protein molecules.
For this reason, we developed an alternative procedure to
load bioactive growth factors within the polymeric nano-
particles. The growth factors were absorbed into the mi-
croparticles only after their production, exploiting the
qualities of water as a vehicle of transport for drugs inside
the polymeric matrix. The high affinity between HYAFF11
and water was ascertained by DSC analysis. This fact was
further demonstrated by the ease of the impregnation pro-
cess with different dyes. HYAFF11 film and microparticles
showed homogeneous absorption by simple contact with the
impregnating substance at room temperature. This absorp-
tion process did not expose the growth factor to any
denaturating agents and the procedure can be performed in
completely sterile conditions.
In vitro release profiles gave important information on
the efficiency of the delivery system for the controlled
release of drugs. An ‘‘in vitro’’ drug release study is indeed
a prerequisite to obtaining correct predictions in order to
design and test the ‘‘in vivo’’ activity of controlled drug
delivery forms [32].
The low release analyzed under physiological conditions
was probably due to the high affinity of the growth factor
for the polymer, thus it was necessary to use promoters to
degrade the polymeric matrix in order to obtain complete
release of growth factors.
The use of enzyme did not lead to release due to the
structure of the HYAFF11, so Na2CO3 was used as sug-
gested in the literature [31, 32]. The salt was able to break
the polymeric structure [32] and thus growth factor release
depended on the degradation rate of the polymer. These
observations confirm that the carboxylic groups in the beta-
glucoronic acid unit are the activation centre of this
enzyme and the total blockage of these groups restricts the
cleavage of beta-glycoside bonds by this enzyme.
Dependence on degradation was demonstrated by the
accurate fitting of K values obtained by the mathematical
model of release. The coefficient correlated linearly with
the salts concentration.
These results demonstrate that growth factor release
from the HYAFF11 nano-particles produced by the GAS
precipitation techniques was mainly driven by erosion
phenomena. Other transport phenomena such as the diffu-
sion process within the polymeric matrix and in the
aqueous solution did not affect the release rate.
Bioactivity experiments designed to investigate in vivo
the performances of growth factors embedded in HYA-
FF11 microspheres were performed. Because PDGF is
known to promote reepithelialization, stimulate granulation
tissue formation, and stimulate collagen deposition, these
models were chosen to help identify its effect on those
processes [19, 20]. The closure of circular wound defects
requires both proliferation (mitosis) and migration of
keratinocytes. Wounds showed an increased reepithelial-
ization when treated with microparticles embedded with
growth factors. The increased epithelialization kinetics
shown by this rat wound model suggests that PDGF
embedded microparticles might be useful in accelerating
healing in wounds by facilitating the process of epitheli-
alization for closure [34]. The fact that PDGF increased the
breaking strength of wounds compared to both vehicle
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controls and microparticles at day six suggests that PDGF
stimulates extracellular matrix and collagen deposition.
These data are in agreement with Werner and Grose [35],
who showed an increase in breaking strength and an
increase in collagen content in PDGF treated incisions [35].
In conclusion, using GAS techniques, HYAFF11 porous
nano-particles suitable for in vivo growth factor delivery
were successfully developed.
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